These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36091311)

  • 1. The tumor-to-liver ratio of the standardized uptake value is a useful FDG-PET/CT parameter for predicting malignant intraductal papillary mucinous neoplasm of the pancreas.
    Utsunomiya T; Ogawa K; Funamizu N; Sakamoto K; Watanabe J; Otani H; Kawaguchi N; Miyagawa M; Iwaki H; Takada Y
    Ann Gastroenterol Surg; 2022 Sep; 6(5):695-703. PubMed ID: 36091311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
    Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
    Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of
    Regenet N; Sauvanet A; Muscari F; Meunier B; Mariette C; Adham M; Moutardier V; Delpero JR; Regimbeau JM; Pessaux P; Paye F; Sa Cunha A; Ansquer C
    J Visc Surg; 2020 Oct; 157(5):387-394. PubMed ID: 32005594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of 18-FDG PET/CT in Detecting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Yamashita YI; Okabe H; Hayashi H; Imai K; Nakagawa S; Nakao Y; Yusa T; Itoyama R; Yama T; Umesaki N; Arima K; Miyata T; Chikamoto A; Baba H
    Anticancer Res; 2019 May; 39(5):2493-2499. PubMed ID: 31092444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility and Limitation of Diagnostic Ability for Different Degrees of Dysplasia of Intraductal Papillary Mucinous Neoplasms of the Pancreas Using
    Hozaka Y; Kurahara H; Oi H; Idichi T; Yamasaki Y; Kawasaki Y; Tanoue K; Jinguji M; Nakajo M; Tani A; Nakajo A; Mataki Y; Fukukura Y; Noguchi H; Higashi M; Yoshiura T; Tanimoto A; Ohtsuka T
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal Papillary Mucinous Neoplasms of the Pancreas: Correlation of Helical Computed Tomography (CT) Features With Pathologic Findings.
    Xu W; Liu X; Zhang J; Yang L
    Acad Radiol; 2017 May; 24(5):609-614. PubMed ID: 28153575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated analysis of host- and tumor-derived markers for predicting high-grade dysplasia and associated invasive carcinoma of intraductal papillary mucinous neoplasms of the pancreas.
    Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Naitoh T; Furukawa T; Unno M
    Surg Today; 2020 Sep; 50(9):1039-1048. PubMed ID: 32124086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil to Lymphocyte Ratio is a Predictive Factor of Malignant Potential for Intraductal Papillary Mucinous Neoplasms of the pancreas.
    Ohno R; Kawamoto R; Kanamoto M; Watanabe J; Fujii M; Ohtani H; Harada M; Kumagi T; Kawasaki H
    Biomark Insights; 2019; 14():1177271919851505. PubMed ID: 31210727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Kuroki H; Taki K; Kaida T; Higashi T; Nitta H; Komohara Y; Beppu T; Takeya M; Baba H
    J Gastrointest Surg; 2015 Dec; 19(12):2171-7. PubMed ID: 26443528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.
    Walter TC; Steffen IG; Stelter LH; Maurer MH; Bahra M; Faber W; Klein F; Bläker H; Hamm B; Denecke T; Grieser C
    Eur Radiol; 2015 May; 25(5):1329-38. PubMed ID: 25433414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm?
    Roch AM; Barron MR; Tann M; Sandrasegar K; Hannaford KN; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2015 Jul; 221(1):48-56. PubMed ID: 26095551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Pancreatology; 2020 Jul; 20(5):895-901. PubMed ID: 32624417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraductal papillary mucinous neoplasm of the pancreas: diagnostic performance of the 2017 international consensus guidelines using CT and MRI.
    Min JH; Kim YK; Kim SK; Kim H; Ahn S
    Eur Radiol; 2021 Jul; 31(7):4774-4784. PubMed ID: 33409798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of pancreatic juice cytology in the diagnosis of pancreatic intraductal papillary mucinous neoplasm.
    Tag-Adeen M; Ozawa E; Ogihara K; Iwatsu S; Akazawa Y; Ohnita K; Adachi T; Sumida Y; Nakao K
    Rev Esp Enferm Dig; 2018 Dec; 110(12):775-781. PubMed ID: 30168338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).
    Fujiyama Y; Kumamoto Y; Nishizawa N; Nakamoto S; Harada H; Yokota K; Tanaka Y; Igarashi K; Oiki H; Okuwaki K; Iwai T; Kajita S; Takahashi H; Tajima H; Kaizu T; Sasaki J; Watanabe M; Yamashita K
    Ann Surg Oncol; 2020 Oct; 27(10):4007-4016. PubMed ID: 32144623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.